Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any muscular dystrophy in which the cause of the disease is a mutation in the LAMA2 gene.
No HPO annotations are available for this condition.
The clinical manifestations of LAMA2 muscular dystrophy (LAMA2-MD) comprise a continuous spectrum ranging from severe congenital muscular dystrophy type 1A (MDC1A) to milder late-onset LAMA2-MD. Those with congenital muscular dystrophy type 1A (MDC1A) typically have neonatal profound hypotonia, poor spontaneous movements, and respiratory failure . Failure to thrive, gastroesophageal reflux, aspiration, and recurrent chest infections necessitating frequent hospitalizations are common. As disease progresses, facial muscle weakness, temporomandibular joint contractures, and macroglossia may further impair feeding and can affect speech. Late-onset LAMA2-MD is characterized by later onset of manifestations, ranging from early childhood to adulthood.
The phenotypic spectrum of LAMA2 muscular dystrophy (LAMA2-MD) ranges from congenital muscular dystrophy type 1A (MDC1A) to LAMA2-MD with onset ranging from early childhood to adulthood (referred to as late-onset LAMA2-MD). No consensus clinical diagnostic criteria for LAMA2-MD have been published.
LAMA2-muscular dystrophy should be suspected in individuals with the following by age of onset; regardless of age; and .
Clinical Findings by Age of Onset
Congenital muscular dystrophy type 1A (MDC1A)
No approved treatments are currently available for LAMA2-related muscular dystrophy. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for LAMA2-related muscular dystrophy, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for LAMA2-related muscular dystrophy. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Table 5. Recommended Surveillance for Individuals with LAMA2 Muscular Dystrophy
System/Concern |
|---|
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
12 publications have been identified in PubMed for LAMA2-related muscular dystrophy. Research spans Basic Science / Preclinical (33%), Case Report / Case Series (25%), and Gene Therapy / Novel Therapeutics (25%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 4 | 33% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 4:32 PM UTC
Common questions about LAMA2-related muscular dystrophy
Source: GeneReviews — "LAMA2 Muscular Dystrophy"
Source: GeneReviews — "LAMA2 Muscular Dystrophy"
Congenital muscular dystrophy type 1A (MDC1A) must be distinguished from other disorders that may present with profound hypotonia (with frog leg posture of the legs), chest deformity, and breathing and feeding problems. The disorders included in the differential diagnosis are other congenital muscular dystrophies, congenital myopathies, congenital myasthenic syndromes, and spinal muscular atrophy. Of note, these disorders are not typically associated with: (1) laminin-2 deficiency detected by immunohistochemical staining of muscle or skin biopsy, or (2) white matter changes on brain MRI. Additional distinguishing features include: • Progressive improvement of tone and strength (in some affected individuals), CK levels near normal range values, diagnostic structural abnormalities on muscle biopsy (by light and electron microscopy), and an absence of joint contractures (even when the disease is severe) in the congenital myopathies; • Multisystemic presentation (e.g., liver and cardiac involvement besides muscle weakness) in congenital metabolic myopathies. Table 2a. Selected Genes of Interest in the Differential Diagnosis of MDC1A
Gene(s) | Disorder | MOI | Distinguishing Clinical Features1 |
|---|---|---|---|
RXYLT1 | Dystroglycanopathies, congenital (OMIM PS236670) | AR | Wide variety of brain eye structural functional abnormalities (may be more severe in Walker Warburg syndrome muscle-eye-brain disease) COL6A1 COL6A2 |
COL6A3 | Collagen type VI disorders (Ullrich CMD)2 | AR3 | Characterized by triad of myopathic features, hyperlaxity, typical skin changes (keratosis pilaris, keloids, striae) BIN1 CCDC78 DNM2 MAP3K20 MTM1 MTMR14 |
SPEG | Centronuclear/myotubular myopathy4 (See X-Linked Myotubular Myopathy.) | XLARAD | Ophthalmoplegia; facial bulbar weakness ACTA1 CFL2 KBTBD13 KLHL40 KLHL41 LMOD3 NEB TNNT1 TPM2 |
TPM3 | Nemaline myopathy4 (OMIM PS161800) | ARAD | Facial bulbar weakness |
RYR1 | Central core disease (OMIM 117000) multiminicore disease (OMIM 255320)4 | ARAD5 | Malignant hyperthermia in some affected individuals |
SELENON | Congenital myopathy w/fiber-type disproportion | ADAR | Insulin resistance |
Rigid spine (congenital) muscular dystrophy (OMIM 602771) | AR | Restrictive respiratory syndrome (nocturnal hypoventilation) CHATCHRNECOLQDOK7GFPT1RAPSN6 | — |
Congenital myasthenic syndromes | ARAD | Facial bulbar weakness; striking motor variability; decremental EMG response or abnormal single-fiber EMG SMN17 | — |
Spinal muscular atrophy | AR | Relatively rapid motor impairment tongue fasciculations; EMG muscle biopsy findings suggest denervation-reinnervation profile; normal nerve conduction studies AD = autosomal dominant; AR = autosomal recessive; CMD = congenital muscular dystrophy; MOI = mode of inheritance; XL = X-linked ... | — |
Source: GeneReviews — "LAMA2 Muscular Dystrophy"
Designated
Exclusivity End |
|---|
Designation Status |
|---|
muscle-tropic derivative adeno-associated virus serotype 9 (AAV9) gene therapy product (MYO-AAV3A.CK8.GNDM.U6.sgHu) | muscle-tropic derivative adeno-associated virus serotype 9 (AAV9) gene therapy product (MYO-AAV3A.CK8.GNDM.U6.sgHu) | Modalis Therapeutics | 2024 | — | Designated |
Angiotensin (1-7) | Angiotensin (1-7) | Constant Therapeutics LLC | 2016 | — | Designated |
Published consensus clinical practice guidelines for congenital muscular dystrophies list recommendations for the following six clinical care areas: neurology, pulmonary, gastrointestinal/nutritional/oral care, orthopedics and rehabilitation, cardiology, and palliative care (full text). Evaluations Following Initial Diagnosis To establish the extent of disease and needs of a child diagnosed with LAMA2 muscular dystrophy (LAMA2-MD), the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with LAMA2 Muscular Dystrophy
System/Concern | Evaluation | Comment |
|---|---|---|
Constitutional | Height, weight, nutritional status | — |
Neurologic | Complete exam by experienced neurologist | To incl assessment of strength For seizures or unexplained fainting or loss of consciousness |
Musculoskeletal | Multidisciplinary neuromuscular clinic assessment by orthopedist, physical medicine, OT/PT | To incl assessment of:; Gross motor fine motor skills; Contractures, clubfoot, kyphoscoliosis; Need for adaptive devices; Need for PT (for improving gross motor skills) /or OT (for improving fine motor skills) |
Feeding | Gastroenterology / nutrition / feeding team | Assessment of:; Nutritional status; For GERD; Constipation; Secretion management, aspiration risk; Optimal position for feeding; Bone health (serum concentrations of vitamin D calcium) |
Oral health | Dental exam | Before age 2 yrs (or at diagnosis) w/attention to enamel defects secondary to GERD, dry mouth, malocclusion/dental crowding interfering w/daily dental care |
Respiratory | By pulmonologist | Assess pulmonary function.; Evaluate for evidence of nocturnal hypoventilation esp in children w/recurrent respiratory infections, FTT, poor cry, or feeding fatigue. |
Neurodevelopmental | Developmental assessment | To incl motor, speech/language eval, general cognitive skills; Eval for early intervention/special education in least restrictive educational environment Cognitive/ |
Psychiatric | As determined by developmental pediatrician / mental health consultant | To determine if there are concerns about learning or mood, behavior, or other psychiatric issues |
Cardiac | By cardiologist | For evidence of cardiomyopathy /or arrhythmia |
Ophthalmologic | By ophthalmologist | For evidence of ophthalmoparesis |
Genetic counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of LAMA2-MD to facilitate medical personal decision making Family/Community |
Treatment of Manifestations in Individuals with Congenital Muscular Dystrophy Type 1A Manifestation/Concern | Treatment | Considerations/Other DD/ID |
Source: GeneReviews — "LAMA2 Muscular Dystrophy"
Avoid the following:
Succinylcholine in induction of anesthesia because of risk of hyperkalemia and cardiac conduction abnormalities
Statins, cholesterol-lowering medications, because of the risk of muscle damage
Source: GeneReviews — "LAMA2 Muscular Dystrophy"
New treatment strategies are being investigated for LAMA2-MD . Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.
Source: GeneReviews — "LAMA2 Muscular Dystrophy"
1 trial found
Evaluation
Frequency |
|---|
feeding | Height, weight, nutritional status, safety of oral intake | At least 2x/yr in 1st 5 yrs |
Neurologic | Neurologic assessment for progression of weakness | Annually or more often for acute exacerbation EEG |
Respiratory | Assessment by pulmonologist of pulmonary function aspiration risk | At least annually |
Neurodevelopmental | Assessment of general developmental progress incl speech-language eval | At least 2x/yr in 1st 5 yrs Cognitive/psychiatric assessment; referral to (pediatric) psychiatry if needed |
Musculoskeletal | Physical medicine, OT/PT assessment of strength, joint range of motion, mobility, self-help skills | Annually Eval of spine for scoliosis |
Cardiac | Eval by cardiologist | For persons w/severe respiratory insufficiency: at least annually; For those w/palpitations, fatigue, or loss of consciousness w/o clear neurologic origin; If no cardiac symptoms: at age 5 yrs, 10 yrs, then every 2 yrs |
Ophthalmologic | By ophthalmologist | Annually Family/Community |
Source: GeneReviews — "LAMA2 Muscular Dystrophy"
Patient case studies |
3 |
25% |
New treatment approaches | 3 | 25% |
Disease patterns and progression | 2 | 17% |
Mohammadi M (2026). [PMID: 41765988](https://pubmed.ncbi.nlm.nih.gov/41765988/). *Journal of human genetics*. [Epidemiology / Natural History]
Reinhard JR (2026). [PMID: 41635088](https://pubmed.ncbi.nlm.nih.gov/41635088/). *Molecular therapy : the journal of the American Society of Gene Therapy*. [Gene Therapy / Novel Therapeutics]
Schedel J (2026). [PMID: 41856211](https://pubmed.ncbi.nlm.nih.gov/41856211/). *Matrix biology : journal of the International Society for Matrix Biology*. [Basic Science / Preclinical]
Oswald S (2025). [PMID: 40296707](https://pubmed.ncbi.nlm.nih.gov/40296707/). *Journal of child neurology*. [Case Report / Case Series]
McGowan TJ (2025). [PMID: 41309582](https://pubmed.ncbi.nlm.nih.gov/41309582/). *Nature communications*. [Basic Science / Preclinical]
Takeuchi E (2025). [PMID: 40720040](https://pubmed.ncbi.nlm.nih.gov/40720040/). *Methods in molecular biology (Clifton, N.J.)*. [Gene Therapy / Novel Therapeutics]
Tan D (2025). [PMID: 40960171](https://pubmed.ncbi.nlm.nih.gov/40960171/). *eLife*. [Basic Science / Preclinical]
McGowan TJ (2025). [PMID: 40225019](https://pubmed.ncbi.nlm.nih.gov/40225019/). *Molecular therapy. Methods & clinical development*. [Gene Therapy / Novel Therapeutics]
de Laat ECM (2024). [PMID: 39681838](https://pubmed.ncbi.nlm.nih.gov/39681838/). *BMC neurology*. [Basic Science / Preclinical]
Djordjevic D (2024). [PMID: 38691940](https://pubmed.ncbi.nlm.nih.gov/38691940/). *Neuromuscular disorders : NMD*. [Case Report / Case Series]
AI-curated news mentioning LAMA2-related muscular dystrophy
Updated Aug 1, 2026
A 1.5-year natural history study evaluates clinical and functional outcome measures in patients with LAMA2-related muscular dystrophy and SELENON-related myopathy. This research contributes to understanding disease progression and potential therapeutic targets.